Medindia

X

Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences

Tuesday, March 7, 2017 Drug News J E 4
Advertisement

WASHINGTON, March 6, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in March 2017.

The Cowen and Company 37th Annual Healthcare Conference in Boston on Tuesday, March 7, 2017. A corporate presentation is scheduled for 8:00 a.m. Eastern Time.

The Oppenheimer 27th Annual Healthcare Conference in New York City on Tuesday, March 21, 2017. A corporate presentation is scheduled for 10:20 a.m. Eastern Time.

The corporate presentations given at the Cowen and Oppenheimer conferences will be available live on Vanda's corporate website, where they also will be archived for 30 days. To access the presentations, go to Vanda's website at www.vandapharma.com and click on the Presentations tab on the Investor Relations page. Please connect to the website several minutes prior to the start of the live presentations.

About Vanda Pharmaceuticals Inc.

Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda, please visit www.vandapharma.com.

Company Contact:Jim KellyExecutive Vice President and Chief Financial OfficerVanda Pharmaceuticals Inc.(202) 734-3428jim.kelly@vandapharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-participation-at-march-2017-investor-conferences-300418636.html

SOURCE Vanda Pharmaceuticals Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
ASPiRA LABs Announces Provider Status with Medi-Ca...
S
Xencor Announces Bruce L.A. Carter, Ph.D., Chairma...